Udayavni Special

Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug


PTI, May 10, 2021, 10:59 AM IST

New Delhi: Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19.

The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib.

Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This collaboration is a step further in the company”s efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.

The company will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets, it added.

“Through the pandemic, Cipla has been at the forefront of COVID care and our partnership with Lilly is a demonstration of our unwavering commitment to care towards patients impacted by COVID-19,” Cipla Ltd MD and Global CEO Umang Vohra noted.

Cipla had last year launched a generic version of antiviral drug remdesivir to treat COVID-19 patients. The drug firm had also introduced antibody detection kits for COVID-19 in the country under the brand name ”ELIFast” in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).

Amid spiralling cases of COVID-19 in the country amid the second wave, drug firms have been collaborating to come out with drugs to treat the highly infectious disease.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

4 ways companies can avoid post-pandemic employee turnover

PDP’s decision making body authorises Mehbooba Mufti to decide on Centre’s invite for talks

Reform comes by sacrificing, not questioning: Salman Khurshid slams G-23

Basavaraj Bommai rejects Congress’ demand for probe into Upper Bhadra project

PM Modi holds meeting with union ministers

Netanyahu to leave prime minister’s residence by July 10

Public parks, gardens to open in Delhi from Monday, outdoor yoga activities to be allowed: DDMA



Related Articles More

Labour ministry mulls extending ABRY deadline till March 2022 to boost fresh hiring

Karnataka Bank declares loan over Rs 160 crore to Reliance Home, Reliance Commercial as fraud

Four of top-10 firms add Rs 68,458.72 cr in m-cap; HUL, Infosys biggest gainers

Automakers initiate production ramp-up with easing of Covid restrictions in states

Zydus Cadila likely to seek EUA for its COVID-19 vaccine next week

MUST WATCH

Manipal IT youngsters plants trees | Planting trees to preserve the Environment

Police Sub Inspector angry on Farmers in Raichur

Belgaum Rescue operation

Remembering Milkha Singh

Dr Ravi Shankar Shetty | Oxygen Condenser Donation

Latest Additions

Raid at temple for conducting marriage without permission

Mandya: Father dies of shock after daughter commits suicide

Lakshadweep admin moots proposal for shifting HC jurisdiction from Kerala to K’taka

4 ways companies can avoid post-pandemic employee turnover

PDP’s decision making body authorises Mehbooba Mufti to decide on Centre’s invite for talks

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.